LONGBIO-B

Tianchen Bio-B staged a sharp afternoon recovery, closing at HK$88.85, up 7.0% from the previous close of HK$83.00, with an intraday range of HK$81.00 to HK$90.40, displaying a 'bottoming-out rebound' pattern. The catalyst was FDA approval of a clinical trial application for LP-003 in peanut allergy. Q4 2025 net loss narrowed 11.7% YoY to HK$42.3 million, though operating loss widened 14.8% to -HK$45.5 million. The stock trades at just 53.6% of its 52-week high, down 32.6% YTD, and well below its MA20 (HK$123.1) and MA60 (HK$126.8), highlighting a sharp disconnect between technical weakness and recent clinical progress. The stock's post-IPO volatility, including a near-28% drop on dilution concerns, however, tempers the rally.

Tianchen Bio-B (Suzhou) Co., Ltd. (1779.HK) traded in a single-day decline during the morning session (BJ 09:30-11:00), closing at HK$92.150, down 5.2% from the previous close of HK$97.200. The stock opened at HK$97.200 and trended lower throughout the session, hitting an intraday low of HK$92.150, which is only 8.41% above its 52-week low of HK$85. The decline is primarily attributed to persistent dilution concerns following the full exercise of the 2,128,950-share greenshoe option after the IPO stabilization period ended. This has triggered a sustained pullback from the 52-week high of HK$165.90 set on June 29, with the stock currently 44.45% below that peak and down 30.08% year-to-date, trading well below its 20-day moving average of HK$129.133 and 60-day moving average of HK$130.306. The Q4 2025 net loss narrowed 11.69% YoY to HK$42.27 million, but zero operating revenue and a PB of 45.21x continue to weigh on valuation. However, the FDA's recent approval of the clinical trial application for LP-003 in peanut allergy offers a potential catalyst for pipeline progress.

Tianchen Bio-B opened low and rebounded sharply in the morning session, dipping to a fresh 52-week low of HK$87.50 before surging to HK$94.55 as of 09:40 BJ, up 5.23% from the previous close of HK$89.85. The reversal was driven by short-covering after the market digested the full exercise of the greenshoe option, which had fueled dilution fears and dragged the stock to a 52-week low of HK$85 on July 8. The company is still down 28.26% YTD and 43.01% below its 52-week high of HK$165.9. Q4 2025 net loss narrowed 11.69% YoY to HK$42.27 million, though operating loss widened to HK$45.53 million. The stock trades well below its MA20 (HK$131.49) and MA60 (HK$131.79), with an average price of HK$88.52 indicating some support, though the sustainability of this rebound remains uncertain.

1779.HK experienced a volatile session today, closing at HK$90.2, down 5.1% from the prior close of HK$95.05, primarily driven by the full exercise of the greenshoe option and subsequent dilution concerns. The morning session opened at HK$99.9 but plunged to an intraday low of HK$85.05, a 10.5% drop; the afternoon recovered from HK$89.0 to an intraday high of HK$95.0 before retreating. Despite positive Phase III data for LP-003 in seasonal allergic rhinitis, which had pushed the stock to a 52-week high of HK$165.9 on June 29, the stock has since retraced 43.19% from that peak, with YTD decline of 28.49%, and trades well below both its 20-day MA (HK$133.633) and 60-day MA (HK$133.402). Q4 2025 net loss narrowed 11.69% YoY to HK$42.27 million, though operating loss widened to HK$45.53 million and EPS remained negative at -HK$0.7039; while the day's low of HK$85.05 precisely matched the 52-week low, providing a technical support level.

Tianchen Bio-B opened higher but reversed lower in early morning trading, reaching HKD 102.600 by 9:32 BJT, down 5.09% from the previous close of HKD 108.100. The decline was primarily driven by persistent dilution concerns following the full exercise of the greenshoe option at HKD 96.06 per share yesterday, which triggered market worries about equity dilution. Volume was thin at only 1,700 shares with turnover of approximately HKD 178,000. Positive Phase III clinical data for core product LP-003 failed to lift the stock today. Financially, Q4 2025 net loss narrowed 11.69% YoY to HKD 42.27 million, though losses remain substantial. The stock has retreated about 28.9% from its 52-week high of HKD 144.300 and trades below the previous close, indicating weak price momentum, though the positive clinical trajectory may provide underlying support.